# Sorrento Therapeutics, Inc. clinical trials: 46 (2026)

ClinicalTrials.gov lists 46 trials with Sorrento Therapeutics, Inc. as lead sponsor, 1 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Sorrento Therapeutics, Inc.: 46 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sorrento-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 46
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 46, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| January 20, 2023 | NCT05692908 | An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis | Sorrento Therapeutics, Inc. | Phase 1 | Withdrawn | Light Chain (AL) Amyloidosis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05692908) |
| October 18, 2022 | NCT05584709 | Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors | Sorrento Therapeutics, Inc. | Phase 1 | Unknown | Advanced Solid Tumor | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05584709) |
| July 25, 2022 | NCT05472649 | Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy | Sorrento Therapeutics, Inc. | Observational | Enrolling by invitation | Long-term Follow-up | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05472649) |
| May 13, 2022 | NCT05372783 | Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents | Sorrento Therapeutics, Inc. | Phase 2 | Withdrawn | COVID-19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05372783) |
| May 6, 2022 | NCT05364840 | Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers | Sorrento Therapeutics, Inc. | Phase 1 | Completed | COVID-19 | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05364840) |
| May 5, 2022 | NCT05361954 | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | Sorrento Therapeutics, Inc. | Phase 1 | Not yet recruiting | Cancer, Cancer of Pancreas, Sarcoma, Hepatic Metastasis, Solid Tumor | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05361954) |
| May 5, 2022 | NCT05361915 | Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer | Sorrento Therapeutics, Inc. | Phase 2 | Suspended | Prostate Cancer, Prostate Cancer Metastatic | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05361915) |
| April 4, 2022 | NCT05308225 | Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | Sorrento Therapeutics, Inc. | Phase 1/2 | Unknown | Multiple Myeloma | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05308225) |
| October 12, 2021 | NCT05074394 | Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection | Sorrento Therapeutics, Inc. | Phase 2 | Withdrawn | COVID-19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05074394) |
| October 5, 2021 | NCT05067257 | Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer | Sorrento Therapeutics, Inc. | Phase 2 | Suspended | Pain, Intractable, Pain Cancer, Pain | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05067257) |
| September 29, 2021 | NCT05060276 | Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors | Sorrento Therapeutics, Inc. | Phase 1 | Withdrawn | Relapsed Solid Neoplasm, Refractory Cancer, Solid Tumor, Adult | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05060276) |
| August 16, 2021 | NCT05007418 | Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma | Sorrento Therapeutics, Inc. | Phase 1 | Unknown | Multiple Myeloma | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05007418) |
| August 5, 2021 | NCT04992247 | Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise | Sorrento Therapeutics, Inc. | Phase 2 | Withdrawn | Covid19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04992247) |
| June 2, 2021 | NCT04909892 | Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise | Sorrento Therapeutics, Inc. | Phase 2 | Withdrawn | Covid19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04909892) |
| June 2, 2021 | NCT04909879 | Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome | Sorrento Therapeutics, Inc. | Phase 2 | Withdrawn | Acute Respiratory Distress Syndrome, Ards | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04909879) |
| May 28, 2021 | NCT04906694 | Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US) | Sorrento Therapeutics, Inc. | Phase 2 | Completed | Covid19 | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04906694) |
| May 28, 2021 | NCT04905836 | Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress | Sorrento Therapeutics, Inc. | Phase 2 | Unknown | Covid19 | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04905836) |
| May 26, 2021 | NCT04903327 | Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress | Sorrento Therapeutics, Inc. | Phase 2 | Terminated | Covid19 | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04903327) |
| May 25, 2021 | NCT04900519 | Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors | Sorrento Therapeutics, Inc. | Phase 1 | Unknown | Solid Tumor, Relapsed Solid Neoplasm, Refractory Tumor | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04900519) |
| May 25, 2021 | NCT04900428 | Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK) | Sorrento Therapeutics, Inc. | Phase 2 | Terminated | Covid19 | 179 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04900428) |
| May 13, 2021 | NCT04885972 | Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis | Sorrento Therapeutics, Inc. | Phase 2 | Unknown | Osteoarthritis, Knee, Knee Osteoarthritis, Knee Pain Chronic | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04885972) |
| March 22, 2021 | NCT04809012 | Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors | Sorrento Therapeutics, Inc. | Phase 2 | Withdrawn | Solid Tumor, Refractory Tumor, Relapsed Solid Tumor | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04809012) |
| February 25, 2021 | NCT04771351 | Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19 | Sorrento Therapeutics, Inc. | Phase 2 | Withdrawn | Covid19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04771351) |
| February 4, 2021 | NCT04738175 | Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19 | Sorrento Therapeutics, Inc. | Phase 1/2 | Withdrawn | Covid19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04738175) |
| February 2, 2021 | NCT04734860 | Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms | Sorrento Therapeutics, Inc. | Phase 2 | Withdrawn | Covid19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04734860) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 17 |
| Phase 1/2 | 4 |
| Phase 2 | 19 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Not applicable | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Withdrawn | 20 |
| Completed | 10 |
| Unknown | 9 |
| Terminated | 3 |
| Suspended | 2 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 18 |
| Osteoarthritis, Knee | 4 |
| Recurrence | 4 |
| Neoplasms | 4 |
| Cancer Pain | 3 |
| Pain | 3 |
| Multiple Myeloma | 3 |
| Pancreatic Neoplasms | 3 |
| Pain, Intractable | 2 |
| Osteoarthritis | 2 |
| Amyloidosis | 2 |
| Breast Neoplasms | 2 |
| Lymphoma, T-Cell, Peripheral | 1 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Biliary Tract Neoplasms | 1 |
| Lymphoma, Extranodal NK-T-Cell | 1 |
| Cholangiocarcinoma | 1 |
| Gallbladder Neoplasms | 1 |
| Mycosis Fungoides | 1 |
| Lymphoma, T-Cell, Cutaneous | 1 |
| Arthritis, Rheumatoid | 1 |
| Sarcoma | 1 |
| Respiratory Distress Syndrome | 1 |
| Acute Lung Injury | 1 |
| Pneumonia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Produce wholesalers in the United States](https://specstream.ai/data/businesses/produce-wholesalers/united-states)
- [Pediatric anesthesiology practices in the United States](https://specstream.ai/data/businesses/pediatric-anesthesiology-practices/united-states)
- [Mortgage brokers in the United States](https://specstream.ai/data/businesses/mortgage-brokers/united-states)
- [Lighting fixture manufacturers in the United States](https://specstream.ai/data/businesses/lighting-fixture-manufacturers/united-states)
- [Infectious disease clinics in the United States](https://specstream.ai/data/businesses/infectious-disease-clinics/united-states)
- [Haitian restaurants in the United States](https://specstream.ai/data/businesses/haitian-restaurants/united-states)
